The perils of pharma M&A (Bloomberg)

Novasecta’s Managing Partner, John Rountree, was asked by Bloomberg to comment on the perils of pharma M&A in an article that investigated the delays in development of AstraZeneca’s ZS-9 product after AZ had acquired ZS Pharma. Reflecting on our experience with listed pharmaceutical companies in general rather than the specifics of the AZ deal, John commented “The pressure to do a deal is immense” and that “If it looks right, the message on due diligence may just be, ‘just make it work because we’re going to do this deal.’”. For more on Novasecta’s perspective on the high prices paid to execute M&A click here, and on the value of partnerships as an alternative to M&A click here. To view the full Bloomberg article, click here.